Dr. Peng Liu 刘鹏
Chief Physician
Department of Breast Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of breast cancer, including modified radical mastectomy, breast-conserving surgery, sentinel lymph node biopsy, and reconstruction. Also provides postoperative chemotherapy, endocrine therapy, and targeted therapy.
Dr. Liu is a Chief Physician and Professor at Sun Yat-sen University Cancer Center with a doctorate in oncology. With 25 years of experience, Dr. Liu has performed over 4,000 breast cancer surgeries. Research includes over 20 SCI publications and leadership in multiple National Natural Science Foundation projects.
Professional roles
- Member, Breast Cancer Group, Professional Committee on Minimally Invasive Tumor Therapy, China Anti-Cancer Association
- Standing Committee Member, Breast Cancer Professional Committee, Guangdong Anti-Cancer Association
- Standing Committee Member, Breast Tumor Branch, Guangdong Precision Medicine Application Society
- Member, Breast Cancer Group, Oncology Branch, Guangdong Medical Association
Name order: in Chinese the family name comes first (Liu Peng). Papers usually list the name as Peng Liu or Liu P.
Selected publications
73 papers on PubMed matched by name and affiliation; 19 as first or senior author since 2016. Most recent first- or senior-author papers:
- Oncogene, 2026 (senior author): circPARPBP promotes cancer stemness and chemoresistance in triple-negative breast cancer through recruiting SRCAP complex to activate CCL20 transcription. PubMed 42168385
- Quant Imaging Med Surg, 2026 (first author): Prognostic prediction in nasopharyngeal carcinoma using multi-region interaction features based on MRI habitat analysis. PubMed 41972088
- IMetaOmics, 2024 (senior author): A glimpse into the future: Integrating artificial intelligence for precision HER2-positive breast cancer management. PubMed 41675540
- Front Immunol, 2024 (senior author): Editorial: Inflammatory Treg reprogramming in the tumor immune microenvironment. PubMed 38715611
- Sci China Life Sci, 2024 (senior author): The burgeoning importance of PIWI-interacting RNAs in cancer progression. PubMed 38198029
- Front Immunol, 2023 (first author): Multi-omics analyses unravel DNA damage repair-related clusters in breast cancer with experimental validation. PubMed 38022619
- Mol Cancer, 2022 (first author): The FUS/circEZH2/KLF5/ feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition. PubMed 36224562
- J Oncol, 2022 (senior author): Circular RNA KIF4A Promotes Liver Metastasis of Breast Cancer by Reprogramming Glucose Metabolism. PubMed 36052282
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion